SenzaGen AB
SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices;… Read more
SenzaGen AB (SENZA) - Total Assets
Latest total assets as of September 2025: Skr98.37 Million SEK
Based on the latest financial reports, SenzaGen AB (SENZA) holds total assets worth Skr98.37 Million SEK as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
SenzaGen AB - Total Assets Trend (2014–2024)
This chart illustrates how SenzaGen AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
SenzaGen AB - Asset Composition Analysis
Current Asset Composition (December 2024)
SenzaGen AB's total assets of Skr98.37 Million consist of 55.8% current assets and 44.2% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr39.61 Million | 35.4% |
| Accounts Receivable | Skr17.64 Million | 15.8% |
| Inventory | Skr3.74 Million | 3.3% |
| Property, Plant & Equipment | Skr1.76 Million | 1.6% |
| Intangible Assets | Skr32.05 Million | 28.6% |
| Goodwill | Skr15.68 Million | 14.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how SenzaGen AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SenzaGen AB's current assets represent 55.8% of total assets in 2024, a decrease from 80.3% in 2014.
- Cash Position: Cash and equivalents constituted 35.4% of total assets in 2024, down from 57.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 42.0% of total assets, an increase from 19.0% in 2014.
- Asset Diversification: The largest asset category is cash and equivalents at 35.4% of total assets.
SenzaGen AB Competitors by Total Assets
Key competitors of SenzaGen AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.17 Billion |
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
China | CN¥1.47 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
SenzaGen AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - SenzaGen AB generates 0.52x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - SenzaGen AB is currently not profitable relative to its asset base.
SenzaGen AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.43 | 6.43 | 25.05 |
| Quick Ratio | 5.07 | 6.03 | 24.77 |
| Cash Ratio | 2.94 | 4.55 | 23.79 |
| Working Capital | Skr44.12 Million | Skr 50.93 Million | Skr 90.33 Million |
SenzaGen AB - Advanced Valuation Insights
This section examines the relationship between SenzaGen AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.19 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | 15.2% |
| Total Assets | Skr111.91 Million |
| Market Capitalization | $9.76 Million USD |
Valuation Analysis
Below Book Valuation: The market values SenzaGen AB's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: SenzaGen AB's assets grew by 15.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SenzaGen AB (2014–2024)
The table below shows the annual total assets of SenzaGen AB from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr111.91 Million | +15.16% |
| 2023-12-31 | Skr97.18 Million | -18.99% |
| 2022-12-31 | Skr119.95 Million | -10.35% |
| 2021-12-31 | Skr133.81 Million | +19.95% |
| 2020-12-31 | Skr111.55 Million | -21.97% |
| 2019-12-31 | Skr142.96 Million | +58.02% |
| 2018-12-31 | Skr90.47 Million | -16.75% |
| 2017-12-31 | Skr108.67 Million | +211.19% |
| 2016-12-31 | Skr34.92 Million | -23.00% |
| 2015-12-31 | Skr45.35 Million | +897.82% |
| 2014-12-31 | Skr4.54 Million | -- |